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Abstract: Quantitative microdialysis is a traditional biophysical affinity determination technique.
In the development of the detailed experimental protocol presented, we used commercially available
equipment, rapid equilibrium dialysis (RED) devices (ThermoFisher Scientific), which means that it is
open to most laboratories. The target protein and test compound are incubated in a chamber partitioned
to allow only small molecules to transition to a larger reservoir chamber, then reversed-phase high
performance liquid chromatography (RP-HPLC) or liquid chromatography–mass spectrometry
(LC–MS) is used to determine the abundance of compound in each chamber. A higher compound
concentration measured in the chamber that contains the target protein indicates binding. As a novel,
and differentiating contribution, we present a protocol for mathematical analysis of experimental data.
We provide the equations and the software to yield dissociation constants for the test compound-target
protein complex up to 0.5 mM KD, and we quantitatively discuss the limitations of affinities in relation
to measured compound concentrations.
Keywords: label free screening; affinity determination; dialysis; KD determination; promiscuity;
aggregation; nonspecific binding; protein binding analysis; chromatography; drug discovery
1. Introduction
Quantitative microdialysis (qµD) is a traditional, yet powerful technique for the analysis of two
important properties of small molecules of interest [1–4]: (a) the diffusability of small molecules,
which is affected by their intramolecular aggregation and their surface binding properties, and (b)
the determination of their affinities to target proteins, using equipment found in many laboratories.
Conceptually, dissolved test compounds may freely move between two chambers partitioned by a
semipermeable membrane that allows only small molecules to pass through. Along with these freely
moving compounds, one chamber also contains either the target protein (to which it is assumed or
known to bind to) or one or more control proteins (which serve to test the selectivity of the target
protein binding reaction). A thermodynamic equilibrium reached in the absence of a protein after a
certain incubation time should result in equal concentrations of free compound in the two chambers. If
the compound engages in nonspecific binding towards the material of the chambers or the separating
membrane, different compound concentrations will be detected between the two chambers, using any
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of the suitable analysis techniques. In the presence of a target protein binding to the test compound,
the two chambers are also expected to contain different compound concentrations (see Scheme 1).
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Analysis of the compound concentrations in each chamber by RP-HPLC or LC–MS will reveal a
higher abundance of the compound present in the protein-containing chamber if the compound binds
favourably to that protein. The signal detected represents the sum of the protein-bound compound,
and free compound. From these concentrations, the amount of compound bound to the protein can be
deduced. Then, since the total amount of protein is known, the binding affinity of the complex can be
calculated. Many highly sophisticated techniques have been developed during the last decades to
analyse and quantify the interactions of small molecules with proteins, including multiple modes of
fluorescence spectroscopy [5], nuclear magnetic resonance (NMR) [6], mass spectrometry [7], affinity
selection [8,9] and size exclusion chromatography [10], just to name a few. We apply all of the above
in our hit and lead identification projects. The power of the qµD technique lies in its applicability
to unlabelled and labelled compounds and proteins, the ease with which it can be set up, and its
cost effectiveness. Very importantly, a substantial amount more about the properties of the small
molecules can be revealed compared to other techniques, and very low affinity interactions up to
KDs of 500 µM can be determined reliably. These advantages make qµD an integral component of
our label-free affinity screening platform (LFAP) [11], which is also compatible with fragment-based
screening and quantification. Here, we present the experimental and computational design of the
qµD process and provide a detailed protocol and standard operating procedure (SOP) for using our
software for KD calculation.
2. Experimental and Computational Design
2.1. Experimental Design
Step 1 of our qµD process is the determination of the appropriate concentration of the small
molecules needed for detection. Non-fluorescent or fluorescently labelled compounds can be analysed
by RP-HPLC. For non-labelled compounds, a concentration series of 10, 25, 50, 75 and 100 µM is
recommended, with 25–50 µM usually falling in the middle of the linear range. Our lab used this
method to confirm hit compounds arising from on-bead screening [12]. Standard library compounds
or fragments that do not contain aromatic components cannot be detected by RP-HPLC in sufficiently
low concentrations for the qµD process. Instead, these compounds were analysed by LC–MS. To find
the appropriate concentration in this case, it must first be established whether the compounds ionise at
all, and in which detection mode. The LC–MS method for concentration determination was detailed
in Section 3. This protocol was established for analysis by a Thermo FisherTM LTQ Orbitrap XLTM.
Adaptation of the protocol to other mass spectrometry instruments should be straightforward for any
lab proficient in mass spectrometry. In Scheme 1 (Step 1), the concentration range comprising of 50, 100,
500, 1000 and 1500 nM, with 250–500 nM being in the middle of the linear range for most compounds,
was derived from an Orbitrap instrument. Step 2 of the qµD analysis process involves simulating the
dialysis process. This will inform the experimentalist as to the most suitable concentration of the target
protein, to maximise the disparity of compound concentrations between the two chambers, within the
detection limits. Therefore, this step is critical to maximise the accuracy of the method. Step 2 was
described in more detail in Section 2.2. Step 3 involves testing whether the compound equilibrates
uniformly enough between the two dialysis chambers in the absence of the protein, to make it suitable
for incubation with the target protein and one or more negative control proteins in Step 4, to test
the compounds potential for unselective or nonspecific binding. It is well known in biochemistry
that proteins need to be tested for their folding state and aggregation potential. On the other hand,
compounds contained in screening libraries, and—more importantly—primary screening hits, are not
as routinely investigated for inherent problematic behaviours. These behaviours often lead to false
positive and false negative results. Dialysis offers a versatile way to address this; it can be used to test
surface binding as a function of buffer composition, pH, additives and other assay variables, as well
as to identify dynamic aggregation and promiscuous binding as a function of concentration. Using
the predefined compound concentration, pc is determined. This should ideally be below 1.10 after
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an appropriate time period in the target incubation step. Now, having simulated the concentration
of the target protein, and proven the purity and suitability of the test compound, Step 4 of the qµD
process may be performed. In Scheme 1 (Step 4), a single incubation experiment with the target
protein and one with BSA as a control is shown. Additional selectivity and specificity controls can be
integrated as needed. The time frame for equilibration can vary as a function of the concentration of
the compounds, affinity to the target or temperature, however a study by Walters [13] demonstrates
equilibrium of 18 diverse drugs covering a wide range of physicochemical properties is achieved
within 6 h. Similar studies by van Liempd et al. [14] and Ye et al. [15] further demonstrate 6 h to be
an adequate equilibration time. We started with 6 h of incubation, defined by the compound-only
experiment. To determine the partition coefficients, the compound concentration needs to be analysed
in both compartments. A high concentration of protein can interfere with the chromatographic
separation, making it desirable to remove the protein prior to analysis. To this end, methods for
protein denaturation and precipitation using organic solvents, acid or heat have been developed [13].
However, we have found that coprecipitation of the compound with the target protein may occur
to a certain extent, in line with observations by Vanholder et al. [16], reducing the reliability of the
subsequent measurement. Furthermore, adding the denaturation agent to the sample results in a large
volume increase, which need to be offset and the original volume established to perform a quantitative
analysis. Hence, we present here a method where no protein precipitation or chromatography of the
protein containing samples is needed to analyse samples by RP-HPLC. In addition, for the MS analysis,
only a simple dilution is required (due to the sensitivity of the mass spectrometer used), which does
not compromise the sample quality. At this dilution it was found that the amount of protein present
was compatible with our LC–MS setup and therefore analyses could occur without interfering with the
compound detection.
2.2. Materials
• Self-sticking plate seal (Sigma-Aldrich, Cat no.: Z369667-100EA);
• Rapid equilibrium dialysis (RED) device reusable base plate (Thermo Fisher Scientific, Cat.
no.: 89811);
• RED device inserts, 8.0 kDa (Thermo Fisher Scientific, Cat. no.: 89809);
• RED device insert removal tool (Thermo Fisher Scientific, Cat. no.: 89812), or a pair of
non-pointy tweezers;
• Assay buffer. A buffer that is compatible with the target protein;
• 20% ethanol. Made from ethanol (Fisher Scientific, product code 10437341, purity ≥ 99.8%) and
Milli Q water;
• Pluronic F127, low UV absorbance, (Thermo Fisher Scientific, Cat. no.: P6867);
• Dimethyl sulfoxide (DMSO) anhydrous, (Sigma Aldrich, Cat. no: 276855, purity ≥ 99.9%;
• Formic acid (FA) for LCMS LiChropur, (Sigma Aldrich, Cat no.: 5.33002, purity 98–100%);
• HPLC grade H2O and Acetonitrile. H2O: Milli Q water with a resistivity ≥ 18 MΩ cm. Acetonitrile
HPLC Plus (Sigma Aldrich, Cat. no.: 34998, purity ≥ 99.9%);
• Trifluoroacetic acid (TFA) for HPLC, (Sigma Aldrich, Cat. no.: 302031, purity ≥ 99.0%);
• 1.5 mL Eppendorf safe-lock tubes (Eppendorf, Cat. no.: 0030120086) or 1 mL glass vials (VWR,
Cat no.: 548-0385, and lids, Cat. no.: 548-0389);
• Chromacol glass insert vials, (VWR, Cat. no.:548-0260);
• Insert vial snap caps (VWR, Cat. no.:548-0265);
• Standard laboratory orbital shaker, such as Ika Schüttler MTS 4 S 2 Microtiter Shaker.
All reagents were used as received.
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2.3. Equipment
• Agilent 1100 series HPLC system
RP-HPLC method: RP-HPLC analysis were performed on an Agilent 1100 series HPLC system,
consisting of a quaternary pump (G1311A), a degasser (G1322A), a well plate autosampler (G1367A), a
fluorescence (FLD) detector (G1321A) and a diode array (DAD) detector (G1315B). The column used
was an Agilent ZORBAX SB-C18, 4.6 mm × 150 mm, 3.5 µm particle diameter and 80 Å pore size.
Analyses were performed using a gradient of solvent A, H2O containing 0.1% trifluoroacetic acid (TFA)
and B, Acetonitrile (MeCN; HPLC grade) containing 0.1% TFA with a flow rate of 0.8 mL/min. The
gradient used: 0–5 min, 5% B; 5–24 min, 5–100% B, 24–26 min, 100% B; 26–27 min, 100–5% B and
27–30 min, 5% B. HPLC traces were always measured at absorptions of 210 nm, 220 nm, 260 nm and
280 nm. All data analyses were performed using the Agilent Chemstation software v.03.01.
• Thermo FisherTM LTQ Orbitrap XLTM.
• Waters Acquity UPLCTM system.
LC–MS method: All LC–MS analyses were performed on a Waters Acquity UPLC system consisting
of a cooled sample manager and a binary solvent manager coupled to the electrospray ionisation (ESI)
source of the LTQ Orbitrap via an in-house filled column, 0.2 mm × 120 mm, 5 µm particle diameter
and 120 Å pore size (ReproSil-Pur 120 C18-AQ, 5 µm). The solvent system for elution was: A—H2O
containing 0.1% formic acid and B—MeCN containing 0.1% formic acid. A standard gradient method
was used for analysis, which was: 0–3 min, 0.5% B; 3–18 min, 70 % B; 18–22 min, 95% B and 22–25 min
0.5% B; with a flow rate of 8 µL/min. The mass analyser was an LTQ Orbitrap (Thermo Finnigan)
with an ESI injection and it was set to record mass data at the start of the gradient. Thermo Xcalibur
software was used to analyse the mass spectra and calculate intensities for generation of calibration
curves and KD determination from equilibrium microdialysis.
2.4. Computational Design-Simulating System Behaviour
The previous microdialysis analysis method presented by Weidemann et al. [12] was based on
solving the necessary differential equations followed by simplifications based on the assumption that the
protein is in large excess over the small molecule tested. Here we present the derivation of a complete
system definition achievable using the symbolic manipulation abilities of Wolfram Mathematica (version
12.1) [17]. Additionally, we included a term to correct for the possible non-complete equilibrium of test
compounds. Whilst a strongly and indefinitely non-equilibrating compound (see for reasons above)
should be excluded from the assay, the inclusion of this term performs a correction for compounds,
which would achieve equilibrium if given enough time. To arrive at the underlying equations governing
a microdialysis experiment, we defined three locations in which compound can exist. These are: free
in the white chamber (since there is no protein), free in the red chamber (unbound but in the presence
of protein) and finally a third virtual compartment–bound to protein in the red chamber. The system
can thus be defined by the following equations.
l0 ∗ (whitevol+ redvol) == ((lwhite ∗whitevol) + ((l f red+ tl) ∗ redvol)),
l f red == pc ∗ lwhite,
tl ∗KD == t f ∗ (l f red),
lred == l f red+ tl,
pt == lred/lwhite
(1)
where l0 is the ligand concentration representing an equal distribution of ligand across both sides of
the partition between red and white volumes at equilibrium, following an amount of ligand being
added to the red volume in the absence of the protein. whitevol and redvol are the volumes of the
red and white chambers, respectively. lfred and lwhite are the concentrations of free ligand in the
red and white chambers, respectively. tl is the concentration of target–ligand complex in the red
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chamber. tf is the concentration of free (unbound to ligand) target protein in the red chamber. KD is the
dissociation constant of the protein–ligand (target–ligand) complex. lred is the overall concentration
of the compound in the red chamber, including the bound and unbound compound. pt is the ratio
between lred and lwhite. pc is the ratio of the compound concentrations in the red and white chambers
in the control experiment in the absence of the protein; ideally this should be equal to 1 as both of these
concentrations would be l0.
This system of equations for lred, lwhite, pt and KD can be solved using Wolfram Mathematica
(version 12.1), allowing it to be fully simulated for experimental planning. Three equations for KD
determination can be produced using each of the three experimentally determined variables: lred,
lwhite and pt. This enables the KD to be determined using a single concentration sample from either
of the chambers, or by sampling both and determining a pt. In addition, the Python [18] code can be
used to perform the simulation of custom microdialysis experiments, reproduce the simulation plots
within this protocol and explore numerous examples; this is freely available under the open source
MIT license at https://github.com/stevenshave/microdialysis.
The above equations defining the system may be manipulated by Mathematica to remove
unknowns and solve for specific member variables. The following code recreates the system:
model = t0 == t f + tl, l0 ∗ (whitevol+ redvol) =
= lwhite ∗whitevol+ lred ∗ redvol, l f red == pc ∗ lwhite, tl∗KD
== t f ∗ (l f red), lred == l f red+ tl, pt == lred/lwhite;
(2)
Which may then be solved for different member variables with intermediate steps of elimination for
unknown variables such as lfred, tl, tf and more, depending on the subject of the formula.
Solve[Simpli f y[Eliminate[model, t f , tl, l f red, lwhite, pt]], lred][[1]]
Solve[Simpli f y[Eliminate[model, t f , tl, l f red, lred, pt]], lwhite][[2]]
Solve[Simpli f y[Eliminate[model,
{
t f , tl, l f red, lwhite, moleslred, moleslwhite, lred
}
]], pt][[2]]
(3)
Notice that in the above calls to Mathematica’s Solve function, we took solutions 1, 2 and finally
2, as signified by the square brackets at the end of each line, choosing the correct polynomial root
produced in an intermediate step determining equations for 1:1 binding. The direct analytical solutions
for lred, lwhite and pt are as follows:
lred = 12(pc2redvol2+pcvalue∗redvol∗whitevol) ∗ (2 ∗ l0 ∗ pc2 ∗ redvol2
+KD ∗ pc ∗ redvol ∗whitevol+ l0 ∗ pc ∗ redvol ∗whitevol+ 2
∗l0 ∗ pc2 ∗ redvol ∗whitevol+ pc ∗ redvol ∗ t0 ∗whitevol
+KD ∗whitevol2 + l0 ∗ pc ∗whitevol2
− √((−2 ∗ l0 ∗ pc2 ∗ redvol2 −KD ∗ pc ∗ redvol ∗whitevol− l0
∗pc ∗ redvol ∗whitevol− 2 ∗ l0 ∗ pc2redvol ∗whitevol− pc
∗redvol ∗ t0 ∗whitevol−KD ∗whitevol2 − l0 ∗ pc
∗whitevol2)2 − 4(pc2 ∗ redvol2 + pc ∗ redvol ∗whitevol)(l02
∗pc2 ∗ redvol2 +KD ∗ l0 ∗ pc ∗ redvol ∗whitevol+ 2 ∗ l02 ∗ pc2
∗redvol ∗whitevol+ l0 ∗ pc ∗ redvol ∗ t0 ∗whitevol+KD ∗ l0
∗pc ∗whitevol2 + l02 ∗ pc2whitevol2 + l0 ∗ pc ∗ t0
∗whitevol2)))
(4)
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lwhite = 12(pc2∗redvol+pc∗whitevol) ∗ (−KD ∗ pc ∗ redvol+ l0 ∗ pc
∗redvol− pc ∗ redvol ∗ t0−KD ∗whitevol+ l0 ∗ pc
∗whitevol+ √(−4(−KD ∗ l0 ∗ redvol−KD ∗ l0 ∗whitevol)(pc2
∗redvol+ pc ∗whitevol)
+(KD ∗ pc ∗ redvol− l0 ∗ pc ∗ redvol+ pc ∗ redvol ∗ t0+KD
∗whitevol− l0 ∗ pc ∗whitevol)2))
(5)
pt =
1
2 ∗KD ∗ redvol ∗

KD ∗ pc ∗ redvol− l0 ∗ pc ∗ redvol
+pc ∗ redvol ∗ t0−KD ∗whitevol− l0 ∗ pc ∗whitevol
+
√√√√√√√
( −KD ∗ pc ∗ redvol+ l0 ∗ pc ∗ redvol− pc
∗redvol ∗ t0+KD ∗whitevol+ l0 ∗ pc ∗whitevol
)2
−
4 ∗KD ∗ redvol
( −l0 ∗ pc2 ∗ redvol−KD ∗ pc ∗whitevol
−l0 ∗ pc2 ∗whitevol− pc ∗ t0 ∗whitevol
)

(6)
With the simulation of concentrations fully defined, the equations for KD determination can be
derived, which also contribute to experimental planning aspects. There are three equations for KD
determination, either by the measured concentration in the white chamber (lwhite), the red chamber
(lred) or a combination of both (expressed as pt). Whilst simulation and production of concentration
plots as shown in Figure 1 would allow determination of KD from y-axis concentrations and x-axis
KD values, direct analytical solutions for KD determination are quicker and more accurate. We may
solve the quantitative microdialysis model previously defined for KD in terms of lred, lwhite and pt,
producing three equations for the determination of KD.
Solve[Simpli f y[Eliminate[model, t f , tl, l f red, lwhite, lred]], KD]
Solve[Simpli f y[Eliminate[model, t f , tl, l f red, lwhite, pt]], KD]
Solve[Simpli f y[Eliminate[model, t f , tl, l f red, lred, ptvalue]], KD]
(7)
Producing the following equations for KD:
KD f rom pt =
−l0 ∗ pc2redvol+ l0 ∗ pc ∗ pt ∗ redvol
−pc ∗ pt ∗ redvol ∗ t0
−l0 ∗ pc2whitevol+ l0 ∗ pc
∗pt ∗whitevol− pc ∗ t0 ∗whitevol
(pc − pt)(pt ∗ redvol+whitevol) (8)
KD f rom lred =

−l02 ∗ pc2 ∗ redvol2 + 2 ∗ l0 ∗ lred ∗ pc2 ∗ redvol2 − lred2 ∗ pc2 ∗ redvol2
+l0 ∗ lred ∗ pc ∗ redvol ∗whitevol
−lred2 ∗ pc ∗ redvol ∗whitevol− 2 ∗ l02 ∗ pc2 ∗ redvol ∗whitevol
+2 ∗ l0 ∗ lred ∗ pc2 ∗ redvol ∗whitevol− l0 ∗ pc ∗ redvol ∗ t0 ∗whitevol
+lred ∗ pc ∗ redvol ∗ t0 ∗whitevol+ l0 ∗ lred ∗ pc ∗whitevol2
−l02 ∗ pc2 ∗whitevol2 − l0 ∗ pc ∗ t0 ∗whitevol2
(
whitevol ∗
(
l0 ∗ pc ∗ redvol− lred ∗ pc ∗ redvol
−lred ∗whitevol+ l0 ∗ pc ∗whitevol
)) (9)
KD f rom lwhite = −
lwhite ∗ (l0 ∗ pc ∗ redvol− lwhite ∗ pc2 ∗ redvol
−pc ∗ redvol ∗ t0+ l0 ∗ pc ∗whitevol− lwhite ∗ pc ∗whitevol)
l0 ∗ redvol− lwhite ∗ pc ∗ redvol+ l0 ∗whitevol− lwhite ∗whitevol (10)
These direct analytical solutions for KD allow analysis of experimental data in terms of the
compound concentration in either chamber, or the ratio between them.
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Figure 1. Protein–ligand complex KD vs. compound concentration in the red and white chambers.
Standard microdialysis system: 100 µL red chamber, 300 µL white chamber, [t0] = 80 µM and [l0] = 50
µM. Distinguishing between high KDs becomes difficult as KDs increase as concentrations converge
and gradients reduce. Maximum sensitivity and lowest error in KD determination will be present at
low KDs (high affinities).
3. Procedure
3.1. Step 1: Obtaining Calibration Curves
1. Run a RP-HPLC analysis of the small molecules under investigation at 200 µM concentration,
usi g the method bove to d termine th purity and ret n ion time (Rt) of the compound.
Additionally, identifying the absorption waveleng h that giv s he strongest absorption and most
stable baseline. We ound that this is usually the optical density (OD) at 210 nm or at 260 nm.
Alternativ ly, for LC–MS, we ran an analysis of the compound at 5 µM using he method bove
with an injection volume of 2 µL. We determined the R and the mass of the protonated molecular
ion of the compound [M+H]+ in the ion chromatogram, with M being the mon isoto ic mass of
the compound.
2. Create a series of dilutions f the small molecules to be tested in the assay buffer with 5% DMSO
and 0.1% Pluronic f127 in HPLC insert vials, giving a total volume per concentration of 100 µL.
The concentrations needed to depend on each individual compound. However, we found that
a versatile initial choice of concentrations, applicable to most compounds, is 10, 25, 50, 75 and
100 µM. If LC–MS is to be used instead, a series of dilutions of 50, 100, 500, 1000 and 1500 nM
are recommended, in an assay buffer with 5% DMSO in HPLC insert vials, at a total volume per
concentration of 50 µL. Pluronic f127 is omitted in this instance as detergents ionise very well so
can cause problems in mass spectrometry.
3. Run RP-HPLC or LC–MS analyses of the dilution series of compounds, in triplicate, using
the method described above. Injection volume 25 µL (RP-HPLC) or 2 µL (LC–MS) for
each concentration.
4. Analyse the data. For RP-HPLC, determine the area under the elution peak at the predetermined
Rt in the particular chromatogram chosen in 3.1.1, and plot peak area versus each of the applied
small molecule concentrations in triplicate. The graph should show a straight line if the analysis
was performed with compound concentrations in the linear range of the detector. Based on our
own analyses, we concluded that the linear range of peak area versus concentration of > 90% of
small molecules tested covered a range between 25 and 200 µM. Fit the data to a linear y = kx
+ d equation using a suitable software (Excel, Origin, GraFit, etc.). These preanalysis runs will
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serve as reference information for the expected peak area for each test compound concentration.
Alternatively for LC–MS, we obtained the ion chromatogram of the compound and determine the
area under the [M+H]+ mass ion peak at its Rt, which was identified in 3.1.1. This ion peak area
represents the total ion count; we plotted this against each of the small molecule concentrations
in triplicate and followed the same procedure as for HPLC above to obtain a calibration curve.
Based on our analyses, the linear range of our LC–MS covered a range between 100 and 1000 nM.
3.2. Step 2: Identification of Appropriate Target Protein Concentration
The simulation of concentrations present over a range of KDs is performed by using either the
accompanying Python code or Microsoft Excel-based workbook; both are available at https://github.
com/stevenshave/microdialysis. Alternatively, the equations derived in Section 2.3 (computational
design–simulating system behaviour) may be translated into a preferred plotting or simulation
environment. Working in a standard unit scale such as micro- or nano- simplifies the input and reduces
the risk of numerical instability. Therefore, micromolar and microliter units were chosen as defaults
for the input, calculations and output evaluation. Described below are the steps necessary to simulate
a ‘standard’ HPLC-analysis-based microdialysis system using an 80 µM protein, a starting ligand
concentration of 200 µM, which equilibrates to 50 µM in the absence of protein, and standard red and
white volumes of 100 and 300 µL respectively. Target–ligand KDs from (fractionally above) 0 to 500 µM
were simulated. These simulations served to ensure that unbound compound concentrations achieved
at the KDs of interest were accurately readable with the equipment used.
Simulation using the Python code:
1. Open the Python program entitled “02_plot_KDvsConcentrations.py” in a text editor and assign
simulation concentrations to the following variables:
a. l0 = 50→ Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 200 µM in the red chamber would
equilibrate to 50 µM in both chambers in a system with standard volumes of 100 and 300
µL for the red and white chambers respectively.
b. t0 = 80→ Protein (target) concentration in the red chamber.
c. redvol = 100→ Volume of the red chamber.
d. whitevol = 300→ Volume of the white chamber.
e. KD_beginning = 0→ Lower boundary of the KD range for the X-axis.
f. KD_end = 500→ Upper boundary of the KD range for the X-axis.
g. pc = 1.0→ pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
2. Save and run the newly edited Python program to produce a plot as shown in Figure 1.
3. To perfom single point accurate measurements and read out the data, edit the Python program
“01_simulate_qud_concentrations.py” and set l0, t0, red and whitevol as defined in the Python
part of Section 3.2, additionally, set kdtl to be the precise value of KD at which to read out the red
and white volume concentrations.
Simulation using the Excel workbook:
1. Open the Excel workbook file entitled “quDSimulation_v1.xlsx” in Microsoft Excel, LibreOffice
calc or a similar compatible spreadsheet program. Fields that should be edited by users to
simulate a system are coloured red, and readout cells are green.
2. Open the sheet entitled ‘Simulation’ and edit the following fields as shown below to simulate the
standard qµD system defined above. The plot produced automatically updates upon eachvariable
manipulation.
a. l0 = 50→ Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 200 µM in the red chamber would
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equilibrate to 50 µM across chambers in a system with standard volumes of 100 and 300
µL for red and white chambers respectively.
b. t0 = 80→ Protein (target) concentration in the red chamber.
c. redvol = 100→ Volume of the red chamber.
d. whitevol = 300→ Volume of the white chamber.
e. KD_end = 500→ Upper boundary of the KD range for the X-axis.
f. pc = 1.0→ pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
3. The updated plot is displayed automatically on the sheet, producing the plot shown in Figure 1.
4. To perfom accurate single-point measurements and read out the data, select the ‘KD to
conc+pValue’ sheet and fill in the same variables as listed in the Excel part of Section 3.2,
adding a new value for ‘KD’ indicating the KD at which to read out the red and white chamber
ligand concentrations.
3.3. Step 3: Compound-only Dialisability Test
1. Define the compound concentration to use based on the peak area as a function of the concentration
analysis performed in 3.1.4; it should lie in the middle of the linear range determined in 3.1.4.
Keep in mind that after full equilibration only 25% of the starting concentration will be detectable
(see qµD process outline above). For example, if the centre of the linear range found is 50 µM for
the RP-HPLC analysis, then one needs to use a starting compound concentration of 200 µM. This
is a direct consequence of the volumes present in the RED device.
2. Prepare at least 900 µL of the assay buffer. When RP-HPLC is used for analysis, this includes 5%
DMSO and 0.1% pluronic f127. For LC–MS, Pluronic f127 is omitted.
3. To produce the standard qµD system modelled in Section 3.2, step 2, prepare a 350 µL solution of
test compounds at 200 µM in the assay buffer with 5% DMSO and 0.1% pluronic f127. Apply
sonication and vortexing to support compound solubilisation, and visually inspect the solution
for precipitation. For LC–MS, prepare a 350 µL solution of test compounds at 40 µM in the assay
buffer with 5% DMSO and use the same methods as above to make sure that the compound is
fully in solution.
4. Clean the base plate thoroughly with 20% ethanol and allow it to dry.
5. Place 3 RED devices into the base plate for each compound to be tested.
6. Add 100 µL of compound solution into the red chamber of each RED device and 300 µL of assay
buffer with 5% DMSO and 0.1% pluronic f127 in the white chamber, respectively. For LC–MS:
add 100 µL of compound solution into the red chamber of each RED device and 300 µL of assay
buffer with 5% DMSO.
7. Seal the base plate with a self-adhesive plate seal to inhibit evaporation.
8. Place the base plate onto an orbital shaker at 250 rpm for 6 h for equilibration. Up to 6 h is the
suggested time by the manufacturers but this needs to be investigated for the compound under
study; some compounds may require an overnight equilibration.
9. After > 6 h equilibration time, harvest 50 µL from each chamber of each RED tube and run
RP-HPLC using the identical gradient and 25 µL injection volume. If fully equilibrated, the
compound concentration in either chamber should be 50 µM. For LC–MS, harvest 10 µL from each
chamber of the RED tube, and dilute 20 ×with 0.1% formic acid solution. Run the diluted solution
using the LC–MS method above, injection volume 2 µL. If fully equilibrated, the compound
concentration in either chamber should be 10 µM and after 20 × dilution it should be 500 nM.
10. Check that the Rt in the chromatographic elution profile of each test sample has not changed from
the condition-setting experiments. Determine the peak area for the compounds in the solutions
taken from the red and the white chamber for each HPLC run. Determine pc from the ratio of
these two peak areas. A well-equilibrated compound should result in a pc of 0.90–1.10. Any
compound showing larger than 10% deviation from 1.00 should be considered for exclusion from
Methods Protoc. 2020, 3, 55 11 of 20
further analysis. For LC–MS, check that the Rt in the ion chromatogram of each sample has
not changed from the condition setting experiments. Determine the mass ion peak area for the
compounds in the solutions taken from the red and white chamber for each LC–MS run. Perform
a data analysis as above using this total ion count.
11. Additionally, if a compound shows full equilibration with 0.90 < pc < 1.10, check for compound
losses, which could occur for a variety of reasons described in the introduction section. If the area
under the chromatographic peaks (or mass ion peak in LC–MS) is within 10% of the one found
during the initial calibration experiment using a 50 µM (500 nM for LC–MS) concentration, it can
be assumed that compound losses are negligible.
3.4. Step 4: Microdialysis Target Protein–Small Molecule Binding assay
1. Place 6 RED devices (3 RED devices containing compounds only, and 3 containing compounds +
target protein) into the cleaned base plate.
2. Prepare 2 mL of assay buffer with 5% DMSO and 0.1% pluronic f127 when HPLC is used for
analysis. When LC–MS is used for analysis, prepare 2 mL of the assay buffer containing 5% DMSO.
3. Prepare 350 µL of 200 µM small molecule solution in the assay buffer with 5% DMSO and 0.1%
pluronic f127, and 350 µL of 200 µM small molecule plus 80 µM protein in the same buffer. For
LC–MS, prepare 350 µL of 40 µM small molecule solution in the assay buffer with 5% DMSO and
350 µL of 40 µM small molecule plus 40 µM protein in the same buffer.
4. Add 3 × 100 µL of 200 µM (or 40 µM) compound solution to 3 red chambers of the RED tubes
followed by adding 3 × 300 µL dialysis buffer in the corresponding white chambers.
5. Add 3 × 100 µL of 200 µM + 80 µM protein (or 40 µM compound + 40 µM protein) solution into
3 red chambers of the RED tubes and add 3 × 300 µL of dialysis buffer in the corresponding
white chambers.
6. Seal plate with the self-adhesive plate seal and place on shaker at 250 rpm for 6 h.
7. After 6 h or overnight incubation, remove the plate from the shaker and harvest 50 µL each
from the red and white chamber of the compound-only samples, as well as 50 µL from the
white chambers of the compound-protein binding samples; and add them to insert vials for the
HPLC analysis. For the LC–MS analysis, take out 10 µL from each red and white chamber of the
compound alone samples as well as from the compound and protein samples.
8. Run these samples on RP-HPLC under the same conditions as above, with an injection volume of
25 µL, or for LC–MS, dilute the 10 µL aliquot 20 × with 0.1% FA solution and run the LC–MS
analysis, injection volume 2 µL.
9. From the resulting chromatograms, obtain peak areas at known Rts for the samples for RP-HPLC.
For LC–MS, obtain mass ion peak areas of the compounds at known Rts.
For compound-only experiments:
10. Determine pc = compound peak area from red chamber/white chamber or determine pc = mass
ion peak area from red chamber/white chamber.
11. This should resemble the data achieved from the compound equilibration test experiments and
should therefore be close to 1.0.
12. For determination of the total amount of compounds in the qµD. Convert the compound peak
area or mass ion peak area obtained in Section 3.3. 11 into compound concentration by using the
calibration curve in Section 3.1. 4. The amount of compound in the chambers can be obtained
by multiplication of the converted compound concentration in the red chamber by 100 µL plus
the converted compound concentration of the white chamber multiplied by 300 µL. This should
yield close to the amount of introduced compound at the start of the dialysis (200 µM × 100 µL =
20 × 10−9 mol for HPLC and 40 µM × 100 µL = 4 × 10−9 mol for LC–MS) indicating no losses
due to adhesion, precipitation or aggregation effects. Note that for LC–MS the solutions were
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diluted 20 × before analysis. Therefore, one needs to multiply by a factor of 20 to obtain the real
concentrations in the RED tube.
For compound-target protein binding experiments:
13. From the HPLC chromatograms of the white chambers, determine the peak area and convert to
compound concentration by using the calibration curve above.
14. Determine the amount of compound in the white chamber by multiplication of the determined
compound concentration with the volume of the white chamber, 300 µL.
15. From Section 3.3. 13 the total amount of compound is known. Therefore, the amount of compound
in the red chamber is the difference between the total amount of compound and the amount of
compound in the white chamber.
16. Calculated the compound concentration in the red chamber by dividing the amount of compound
in the red chamber by 100 µL.
17. Determine pt by dividing the compound concentration of the red chamber by that of the white
chamber. For LC–MS, determine pt by dividing the compound mass ion peak area of the red
chamber by that of the white chamber obtained in Section 3.3. 9.
3.5. Step 5: Use the Software to Determine the Dissociation Constant (KD) of the Compound to the Target
Protein by Using the Red/White Chamber Concentrations or pt Values
Determination of the dissociation constants (KDs) can be performed by either using the
accompanying Python code or Microsoft Excel-based workbook, both available at https://github.
com/stevenshave/microdialysis. Below we performed the steps necessary to determine a KD for
a ‘standard’ HPLC-analysis-based microdialysis system using 80 µM protein, a starting ligand
concentration of 200 µM, equilibrating to 50 µM in the absence of protein and standard red and white
volumes of 100 and 300 µL respectively. There were three equations for KD determination, either by
the measured concentration in the white chamber (lwhite), the red chamber (lred), or a combination of
both, as expressed as pt.
KD determination using the Python code on single point measurement data:
1. To determine a KD based on only a single point measurement of the white chamber concentration,
open the Python file entitled ‘03_deriveKD_from_lwhite.py’ in a text or code editor and assign the
following variables, taking care to input the correct value for lwhite as the measured concentration
of ligand in the white chamber and run the program to read out the KD:
a. l0 = 50, Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
b. t0 = 80, Protein (target) concentration present in the red chamber.
c. redvol = 100, Volume of the red chamber.
d. whitevol = 300, Volume of the white chamber.
e. lwhite, The ligand concentration as measured in the white chamber.
f. pc, pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
2. To determine a KD based on only a single point measurement of the red chamber concentration,
open the Python file entitled ‘03_deriveKD_from_lred.py’ in a text or code editor and assign the
following variables, taking care to input the correct value for lred as the measured concentration
of ligand in the red chamber and run the program to read out the KD:
a. l0 = 50, Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
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equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
b. t0 = 80, Protein (target) concentration present in the red chamber.
c. redvol = 100, Volume of the red chamber.
d. whitevol = 300, Volume of the white chamber.
e. lred, The ligand concentration as measured in the red chamber.
f. pc, pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
3. To determine a KD based on a pt derived from single point measurements open the Python file
entitled ‘03_deriveKD_from_pt.py’ in a text or code editor and assign the following variables,
taking care to input the correct value for pt as the ratio of compound concentration the the red
versus white chambers and run the program to read out the KD:
a. l0 = 50, Compound (ligand) concentration achieved after equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
b. t0 = 80, Protein (target) concentration present in the red chamber.
c. redvol = 100, Volume of the red chamber.
d. whitevol = 300, Volume of the white chamber.
e. pt, The pt value, which is the concentration of ligand in the red chamber divided by the
concentration of ligand in the white chamber.
f. pc, pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
KD determination using the Python code on multiple replicates of measurement data:
1. To determine a KD based on multiple replicate measurements of compound concentration in the
white chamber, open ‘04_deriveKD_from_multiple_lwhite.py’ in a text or code editor. Comments
in the file provide instructions in line with the following:
a. Assign the experimental variables as descibed in Section 3.5. 1 above, setting l0, t0, redvol
and whitevol.
b. If 3 measurements of compound concentration lwhite have been made, calculate the mean
and standard deviation of these variables using numpy (val1, val2 and val3 bellow are
measurement replicates):
i. lwhite_mean = np.mean([val1, val2, val3]);
ii. lwhite_std = np.std([val1, val2, val3]).
c. Assign lwhite to be a newly constructed Python uncertainties package ufloat object.
i. lwhite = ufloat(lwhite_mean, lwhite_std).
d. If multiple pc values have been derived, the pc variable may be assigned to a ufloat object
constructed as:
i. pc_mean = np.mean([val1, val2, val3]);
ii. pc_std = np.std([val1, val2, val3]);
iii. pc = ufloat(pc_mean, pc_std).
e. Alternatively, a single pc value may be assigned as in 3.5.
2. To determine a KD based on multiple replicate measurements of compound concentration in the
red chamber, open ‘04_deriveKD_from_multiple_lred.py’ in a text or code editor. Comments in
the file provide instructions in line with the following:
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a. Assign the experimental variables as descibed in Section 3.5. 1 above, setting l0, t0, redvol
and whitevol.
b. If 3 measurements of compound concentration lred have been made, calculate the mean
and standard deviation of these variables using numpy (val1, val2 and val3 bellow are
measurement replicates):
i. lred_mean = np.mean([val1, val2, val3]);
ii. lred_std = np.std([val1, val2, val3]).
c. Assign lwhite to be a newly constructed Python uncertainties package ufloat object.
i. lred = ufloat(lred_mean, lred_std).
d. If multiple pc values have been derived, the pc variable may be assigned to a ufloat object
constructed as:
i. pc_mean = np.mean([val1, val2, val3]);
ii. pc_std = np.std([val1, val2, val3]);
iii. pc = ufloat(pc_mean, pc_std).
e. Alternatively, a single pc value may be assigned as in Section 3.5. 1.
3. To determine a KD based on multiple replicate measurements of pt, open
‘04_deriveKD_from_multiple_pt.py’ in a text or code editor. Comments in the file provide
instructions in line with the following:
a. Assign the experimental variables as descibed in Section 3.5. 1 above, setting l0, t0, redvol,
and whitevol.
b. If 3 measurements of pt have been made, calculate the mean and standard deviation of
these variables using numpy (val1, val2 and val3 bellow are measurement replicates):
i. pt_mean = np.mean([val1, val2, val3]);
ii. pt_std = np.std([val1, val2, val3]).
c. Assign lwhite to be a newly constructed Python uncertainties package ufloat object.
i. pt = ufloat(pt_mean, pt_std).
d. If multiple pc values have been derived, the pc variable may be assigned to a ufloat object
constructed as:
i. pc_mean = np.mean([val1, val2, val3]);
ii. pc_std = np.std([val1, val2, val3]);
iii. pc = ufloat(pc_mean, pc_std).
e. Alternatively, a single pc value may be assigned as in Section 3.5. 1.
KD determination using the Excel workbook code:
1. To determine a KD based on only the white chamber concentration, open the Excel file entitled
‘quDSimulation_v1.xlsx’ in Microsoft Excel, LibreOffice calc, or similar compatible spreadsheet
program. Go to the tab named ‘lwhite to KD’ and assign the following variables, taking care to
input the correct value for lwhite as the measured concentration of ligand in the white chamber.
The readout of KD will update with every change of input variable:
a. l0 = 50→ Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
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b. t0 = 80→ Protein (target) concentration present in the red chamber.
c. redvol = 100→ Volume of the red chamber.
d. whitevol = 300→ Volume of the white chamber.
e. lwhite→ The ligand concentration as measured in the white chamber.
f. pc→ pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
2. To determine a KD based on only the red chamber concentration, open the Excel file entitled
‘quDSimulation_v1.xlsx’ in Microsoft Excel, LibreOffice calc, or similar compatible spreadsheet
program. Go to the tab named ‘lred to KD’ and assign the following variables, taking care to
input the correct value for LRED as the measured concentration of ligand in the red chamber. The
readout of KD will update with every change of input variable:
a. l0 = 50→ Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
b. t0 = 80→ Protein (target) concentration present in the red chamber.
c. redvol = 100→ Volume of the red chamber.
d. whitevol = 300→ Volume of the white chamber.
e. lred→ The ligand concentration as measured in the red chamber.
f. pc→ pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
3. To determine a KD based on pt, open the Excel file entitled ‘quDSimulation_v1.xlsx’ in Microsoft
Excel, LibreOffice calc or a similar compatible spreadsheet program. Go to the tab named ‘pt to
KD’ and assign the following variables, taking care to input the correct value for PT_VALUE as
the measured and calculated pt value. The readout of KD will update with every change of input
variable:
a. l0 = 50→ Compound (ligand) concentration achieved at equilibrium in both chambers in
the absence of the protein. A starting concentration of 100 µM in the red chamber would
equilibrate to 25 µM across chambers in a system with standard volumes of 100 and 300 µL
for red and white chambers respectively.
b. t0 = 80→ Protein (target) concentration present in the red chamber.
c. redvol = 100→ Volume of the red chamber.
d. whitevol = 300→ Volume of the white chamber.
e. pt→ The pt value, which is concentration of the ligand in the red chamber divided by the
concentration of the ligand in the white chamber.
f. pc→ pc = 1 indicates that the compound equilibrates perfectly in the control qµD run.
4. Expected Results
4.1. Simulation of the qµD Experiment as a Function of the Concentrations and KDs
With equations established to simulate the concentration of compound present in each chamber,
the expected red and white chamber concentrations can be evaluated in relation to the sensitivity of
the chosen instruments. Since KD determination is achieved by the accurate comparison of compound
concentrations in the two chambers, or by inferring either one from the other in the case of only using
one concentration, it is important that the experimental setup is such that a sensitive quantitative and
accurate concentration determination is possible over the range of conditions of most interest. This
may direct the experimental design to search for high or low affinity hits in screening campaigns and
directly influences assay sensitivity, threshold values and Z’ values as an assessment of assay quality.
Methods Protoc. 2020, 3, 55 16 of 20
Figure 1 demonstrates how compound concentrations in each of the microdialysis chambers
converged as the KD increased. The simulation was performed as step 2 of the protocol and is necessary
to understand the range of KDs resolvable as a function of concentrations and the accuracy of the
instruments used to measure them. The simulation shows a typical setup for readout via HPLC, in
which 80 µM of target protein was placed into the red chamber, along with an amount of ligand, which
in the absence of the protein would equilibrate to 50 µM. Large separation of concentrations at low KDs
(high affinity) allowed for a confident and accurate assignment of KD from concentrations. At the upper
end of the simulated KD range between 400 and 500 µM, the concentration differed minimally, making
a direct assignment of KD within this range less accurate. This difficulty in confidently assigning high
KDs is further demonstrated in Scheme 1, Step 5, whereby pt is calculated and shown to be converging
to what would be pc.
Figure 2 further demonstrated the difficulty in using pt to assign high KDs, with the KDs of 300 and
500 µM producing ptvalues of 1.247 and 1.153 respectively, lred values of 29.366 and 27.760 respectively
and lwhite values of 23.545 and 24.081 µM, respectively.
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Figure 2. The protein–ligand complex KD vs. the pt. standard microdialysis system, 100 µL red chamber,
300 µL white chamber, [t0] = 80 µM and [l0] = 50 µM. At higher concentrations, the ratio of the
compound within each chamber reaches equilibrium as the pt value becomes asymptotic to pt = 1. Very
precise concentration measurements would be needed to accurately determine high KDs or identify
them as hit compounds.
4.2. Exemplaric Considerations on the Accuracy of KD Determinations
Differentiating the three equations for KD with respect to lred, lwhite and pt allows investigation of
the rate of change of KD as a function of changing concentrations, further illustrating the importance of
accurate concentration determination. Using the standard microdialysis system simulated in Figures 1
and 2, where p0 was 80 µM, l0 was 50 µM and the standard volumes of 100 and 300 µL for the red
and white chambers, differentiation with respect to lred, lwhite and pt shows gradients along with
concentrations and pt values present at intervals between 1 and 500 µM. From these values given in
Table 1, we clearly see the instantaneous gradient present at red and white concentrations was smaller
at KD levels of 1 vs. 500 µM KD values. A unit change in red or white concentration invoking almost a
200-fold instantaneous change in KD at 500 vs. 1 µM KDs. As the change in the KD value as calculated
by pt was so large, it was suggested that only one singular concentration be used for KD determination.
Ideally this would be the red chamber, which had the smallest gradient with respect to the compound
concentration present across all KD values. However, with protein present, steps for compound
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concentration determination were further extended with the removal of the protein from samples.
A general rule is therefore suggested whereby the white chamber compound concentration (lwhite)
was used for KD determination. The relationship between lred and lwhite for perfectly equilibrating
compounds (pc = 1.00) shows identical fold-changes in gradient across KDs compared to a baseline
gradient at a KD of 1 µM. We concluded that the qµD method was best suited for determination of KDs
less than 200 µM.
Table 1. Values for lred, lwhite and pt, and first derivatives thereof over a range of KDs for the standard
system where p0 is 80 µM, l0 is 50 µM and the red and white chambers have standard volumes of 100
and 300 µL, respectively. A unit change in lred concentration at 55.3 µM (KD of 500 µM) results in a
193-fold change in KD readout compared to the 108 µM concentration (KD 1 µM level). Similar changes
are seen in the white chamber.
lred lwhite pt
KD
Concentration
(µM)
∂KD/∂lred
(Fold Change from
1 µM)
Concentration
(µM)
∂lKD/∂lwhite
(Fold Change from
1 µM)
Value
∂KD/∂pt
(Fold Change from
1 µM)
1 108.1032 −0.5553 (1) 30.6323 1.6659 (1) 3.5291 −7.8158 (1)
100 68.304 −8.6209 (16) 43.8987 25.8628 (16) 1.5559 −249.2 (32)
200 61.2679 −23.2953 (42) 46.244 69.8859 (42) 1.3249 −747.259 (96)
300 58.1682 −44.6309 (80) 47.2773 133.8926 (80) 1.2304 −1496.34 (192)
400 56.4121 −72.6318 (131) 47.8626 217.8954 (131) 1.1786 −2495.81 (319)
500 55.2795 −107.299 (193) 48.2402 321.8969 (193) 1.1459 −3745.46 (479)
Figure 3 illustrates the possible KD range calculated using a detection method and handling
technique, which introduced a ±5% (measured at the 2 σ confidence level) error. The valid 2σ KD
ranges for the standard HPLC example system used above, with lwhite concentrations of 35, 40 and 45
µM were: 8.9–14.9 µM, 31.9–50.1 µM and 99.4–191.9 µM, respectively.Methods Protoc. 2020, 3, x FOR PEER REVIEW 18 of 20 
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Figure 3. KD determination using a 5% concentration error. Standard microdialysis system, 100 µL red
chamber, 300 µL white chamber, [t0] = 80 µM and [l0] = 50 µM. lwhite compound concentrations of 35
(red), 40 (green) and 45 µM (blue) give rise to KD ranges of 8.9–14.9 µM, 31.9–50.1 µM and 99.4–191.9
µM respectively.
An accurate determination of KDs will always depend on the accuracy of the concentration
determination, which is linked to instrument sensitivity and handling. The impact of these errors may
be minimised through proper planning and simulation, knowing the KD ranges of most interest and
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setting rejection criteria for hit KDs. The mathematical treatment of the microdialysis system as defined
in this protocol also increases the accuracy of the technique compared to the previously published
simplified equations, which rely on the assumption that the amount of free protein is in great excess of
the bound protein. Our protocol does not include such assumptions and represents a correct treatment
of the system.
System simulation and reproduction of all plots may be achieved using the supplied Python code
or the included Microsoft Excel workbook at https://github.com/stevenshave/microdialysis.
4.3. Experimental Results
In the following we summarized the outcome of two qµD experiments, which were performed
with primary hits from a plate-based size-exclusion chromatography screen [10] against two validated
human cancer targets and one antibacterial target. This method allowed the identification of low
affinity binders in the low mM KD range. However, quantification was only relative and exact affinity
determination of the target was cumbersome. Additionally, compounds that aggregate in solution
at the assay concentrations can result in false positives, since they are spun through a size exclusion
membrane as fast as if they were bound to the target protein. Therefore, qµD was applied to check the
aggregation and surface binding properties of the primary hit compounds and if suitable, their target
binding KDs. For compounds 1–3 the RP-HPLC analysis was applied, for compound 4 the analysis
was performed using an LC–MS read out (Table 2).
Table 2. Summary of results obtained with the qµD protocol on compounds, which showed low
dialisability (1), nonspecific binding (2), strong specific and weak nonspecific binding (3) and a specific
binder, which affinity to the target was compared to the affinity determined by NMR.
Compound # [l0] (µM) [t0] (µM) pc pt ps (BSA) Comment
1 25 80 1.41 ± 0.02 NA NA Non-equilibrating compound.
2 25 80 1.02 ± 0.01 1.15 ± 0.03 1.29 ± 0.05
Equilibrating compound, but it binds
BSA stronger than to the target
protein; 603 ± 154 µM vs. 278 ± 57
µM–assuming 1:1 binding.
3 25 80 1.02 ± 0.01 1.21 ± 0.01 1.11 ± 0.01
Equilibrating compound, KD = 405 ±
35 µM to target protein, and 882 ± 57
µM to BSA–assuming 1:1 binding.
4 10 40 0.99 ± 0.03 1.21 ± 0.04 NA Well-equilibrating compound, KD =171 ± 34 µM.
After establishing the calibration curve via RP-HPLC and using the simulation to obtain a suitable
protein concentration (t0 = 80 µM), the equilibration of compounds in the absence of the protein was
performed to obtain a pc value from a 100 µM starting compound concentration (l0 = 25 µM). After a
dialysis time of 6 h and an overnight incubation (16 h), the resulting pc value for compound 1 based on
a decorated phenylpiperazine scaffold was significantly higher than the set threshold of 1.10. This
compound, therefore, never reached equilibrium. Hence, it could not be used for KD determination
and was excluded from the hit to lead processes.
In contrast, compound 2 based on a pyridin-2-one scaffold equilibrates well with a pc of 1.02,
reached within 6 h from a starting compound concentration of 100 µM and protein concentration of 80
µM in the red chamber (l0 = 25 µM). Unfortunately, when the experiment was performed with its target
protein and BSA control, pt was less than ps suggesting that the compound binds to BSA with higher
affinity than to its target protein with KDs of 278 ± 57 µM and 603 ± 154 µM respectively. Compound 3
based on a pyridazine scaffold also equilibrated well with pc = 1.02. In the presence of 80 µM of its
target protein and a starting compound concentration of 100 µM (l0 = 25 µM), qµD yielded a pt = 1.21.
The BSA binding test resulted in ps = 1.11, suggesting that although this compound demonstrated
some low affinity binding with a calculated KD of 882 ± 57 µM to BSA, it possessed a higher affinity to
its target protein with a KD of 405 ± 35 µM. The binding of compound 4 also containing a decorated
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phenylpiperazine scaffold had been validated previously using NMR. Therefore, further specificity
controls against proteins such as BSA were not carried out at this stage. As seen in Table 2, the pc value
was 0.99, when incubated with 40 µM protein and at a starting compound concentration of 40 µM
(l0 = 10 µM), indicating that this compound was fully equilibrated after 16 h incubation. The pt value
in the presence of its target protein was determined to be 1.21, which corresponded to a dissociation
constant (KD) of 171 ± 34 µM; in strong agreement with the KD of 154 ± 30 µM determined via 2D
HSQC NMR titrations, with compound concentrations ranging between 0 and 2 mM.
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